Citigroup Inc Fennec Pharmaceuticals Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Citigroup Inc holds 18,626 shares of FENC stock, worth $123,862. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,626
Previous 17,234
8.08%
Holding current value
$123,862
Previous $86,000
36.05%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.7MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$27.1 Million0.71% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$16 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.25MShares$15 Million11.1% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$7.9 Million0.0% of portfolio
-
Dg Capital Management, LLC New York, NY1.11MShares$7.41 Million2.94% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $173M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...